Viventia Biotechnologies Inc. (“Viventia”) maintains two facilities, a corporate head office located in Mississauga, Canada and a state-of-the-art 32,000 square foot cGMP Manufacturing, research development unit in Winnipeg, Canada.

Viventia’s Mississauga facility houses Clinical, Medical and  Regulatory Affairs, Intellectual Property/Contracts and Finance/Accounting/Administration groups. The facility occupies approximately 3,100 square feet of space in a two-storey commercial building close to Toronto’s Pearson International Airport. 

Viventia’s Winnipeg facility houses both a Research & Development component along with a fully integrated, cGMP-compliant production facility.  Through the integration of R&D with the cGMP facility, Viventia has built the infrastructure and capabilities that offer a comprehensive, ‘bench to bedside’ discovery engine, capable of developing human antibodies against unique cell surface targets, optimizating and reengineering those antibodies as therapeutic products, and the production of those antibodies for use in clinical trials.  The facility occupies approximately 31,400 square feet in a single one-storey building that sits on ~1 acre in the Fort Garry Industrial Park.